24th July 2018
A collaborative paper written by our i2i Diabetes workshop expert speakers namely:
amongst others, have produced this outstanding document!
The Committee worked together to develop this review article, providing a summary of relevant data regarding the use of SGLT2i medicines and focusing on specific considerations for appropriate prescribing within the T2DM management pathway. In addition, a benefit/risk tool has been provided that summarises many of the aspects discussed in this review. The tool aims to support clinicians in identifying the people most likely to benefit from SGLT2i treatments, as well as situations where caution may be required.
Take a read of this via the following link: